MAPT and Alzheimer disease: Donanemab, tested in the TRAILBLAZER-ALZ 2 study in early symptomatic AD, similarly reduced amyloid burden and achieved roughly 30–35% slowing of clinical decline, with the clearest effect in patients with intermediate tau burden on positron emission tomography [39].